Loss of control of legs and drugs of ingredients of rivaroxaban - a phase IV clinical study of FDA data


Summary:

Loss of control of legs is found among people who take drugs with ingredients of rivaroxaban, especially for people who are female, 60+ old , have been taking the drugs for < 1 month. This phase IV clinical study is created by eHealthMe based on reports of 215,205 people who have side effects when taking drugs with ingredients of rivaroxaban from the FDA, and is updated regularly.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Rivaroxaban, Xarelto.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.


On Oct, 01, 2022

215,205 people reported to have side effects when taking drugs with ingredients of rivaroxaban.
Among them, 21 people (0.01%) have Loss of control of legs


What is Loss of control of legs?

Loss of control of legs is found to be associated with 719 drugs and 458 conditions by eHealthMe.

Number of reports submitted per year:

Could drugs with ingredients of rivaroxaban cause Loss of control of legs?

Time on drugs with ingredients of rivaroxaban when people have Loss of control of legs *:

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Loss of control of legs when taking drugs with ingredients of rivaroxaban *:

  • female: 52.94 %
  • male: 47.06 %

Age of people who have Loss of control of legs when taking drugs with ingredients of rivaroxaban *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 14.29 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 85.71 %

Conditions people have *:

  1. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 8 people, 38.10%
  2. Osteoporosis (bones weak and more likely to break): 5 people, 23.81%
  3. Primary Myelofibrosis (primary disorder of the bone marrow): 4 people, 19.05%
  4. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 19.05%
  5. High Blood Pressure: 4 people, 19.05%
  6. Pulmonary Hypertension (increase in blood pressure in the lung artery): 2 people, 9.52%
  7. Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 2 people, 9.52%
  8. Depression: 2 people, 9.52%
  9. Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 2 people, 9.52%
  10. Gait Disturbance: 2 people, 9.52%

Other drugs people take *:

  1. Aldactone: 4 people, 19.05%
  2. Alendronic Acid: 4 people, 19.05%
  3. Lasix: 3 people, 14.29%
  4. Cymbalta: 3 people, 14.29%
  5. Ampyra: 3 people, 14.29%
  6. Advair Hfa: 2 people, 9.52%
  7. Biotin: 2 people, 9.52%
  8. Ocrevus: 2 people, 9.52%
  9. Opsumit: 2 people, 9.52%
  10. Oxybutynin: 2 people, 9.52%

Other side effects people have besides Loss of control of legs *:

  1. Fall: 12 people, 57.14%
  2. Weakness: 9 people, 42.86%
  3. Gait Disturbance: 9 people, 42.86%
  4. Urinary Tract Infection: 7 people, 33.33%
  5. Joint Pain: 6 people, 28.57%
  6. Tremor (trembling or shaking movements in one or more parts of your body): 6 people, 28.57%
  7. Dizziness: 5 people, 23.81%
  8. Pain In Extremity: 5 people, 23.81%
  9. General Physical Health Deterioration (weak health status): 5 people, 23.81%
  10. Cerebral Atrophy (decrement in size of brain): 4 people, 19.05%

* Approximation only. Some reports may have incomplete information.


How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drugs with ingredients of rivaroxaban, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on rivaroxaban. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: